A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis

Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved. UDCA treatment has an uncertain impact on disease outcomes and has been reported in hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Dennis D., Mack, Cara, Kerkar, Nanda, Miloh, Tamir, Sundaram, Shikha S., Anand, Ravinder, Gupta, Ashutosh, Alonso, Estella, Arnon, Ronen, Bulut, Pinar, Karpen, Saul, Lin, Chuan‐Hao, Rosenthal, Philip, Ryan, Matthew, Squires, Robert H., Valentino, Pamela, Elsea, Sarah H., Shneider, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824074/
https://www.ncbi.nlm.nih.gov/pubmed/31701072
http://dx.doi.org/10.1002/hep4.1421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824074/
https://www.ncbi.nlm.nih.gov/pubmed/31701072
http://dx.doi.org/10.1002/hep4.1421

Ejemplares similares